FDA Approves Zanubrutinib for Waldenstrom Macroglobulinemia

The FDA has granted approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with Waldenstrom macroglobulinemia (WM). "Bruton tyrosine kinase (BTK) inhibition is an emerging standard of care for WM," wrote Constantine Si Lun Tam, MBBS, MD, FRACP, FRCPA, Professor at the Peter MacCallum Cancer Centre in Australia, and colleagues, in their publication of the ASPEN study results (NCT03053440), on which the approval was based. "ASPEN is a randomized phase 3 study comparing zanubru...
Continue reading

Caring for Patients With Aggressive Non-Hodgkin Lymphoma: Maria R. Badillo, MSN, RN, OCN®, CCRP

Non-Hodgkin lymphoma (NHL) is one of the most common cancers, comprising 4% of all cancers in the United States. Although non-Hodgkin lymphoma can occur at any age, more than half of all patients are 65 years old or older. Efforts are ongoing to find new and better ways to treat non-Hodgkin lymphoma. In this interview, Maria Badillo, MSN, RN, OCN®, CCRP, a Research Nurse Manager at The University of Texas MD Anderson Cancer Center, talks about the challenges and strategies involving the nursing ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.